Once upon a time, Chinese API companies were once misunderstood as low-end manufacturing factories. In fact, during the industrial upgrading process, domestic API firms have long shed this label. They started with conventional bulk API businesses in the early years, and later shifted to high-barrier specialty APIs, patented APIs and biopharmaceutical raw materials.
This transformation is jointly driven by policy guidance, profit pursuit and technological accumulation. No longer content with the positioning of a "global manufacturing hub", companies have embedded themselves into the high-value global pharmaceutical industrial chain by mastering more complex synthetic processes and complying with stricter regulatory standards. This marks a pivotal leap for the entire industry from cost-based competition to technology and quality-driven competition.
Representative enterprises in this regard include Hisun Pharmaceutical and Guobang Pharmaceutical.
As a time-honored pharmaceutical enterprise based in Zhejiang Province, Hisun Pharmaceutical has proactively undergone transformation in recent years. Beyond its traditional API and generic drug businesses, it has actively expanded into new sectors including general health, medical aesthetics, animal health and innovative drugs. This strategic move shields its overall performance from downturns caused by industry cyclicality relying solely on API and generic drug businesses. After navigating the growing pains of transformation, Hisun Pharmaceutical has returned to a growth trajectory, and this established pharmaceutical company is poised to embrace a new lease of life.
Guobang Pharmaceutical, by contrast, has made aggressive layouts in the animal health business. Apart from human pharmaceuticals, the animal health market remains an undervalued sector. After years of development, Guobang Pharmaceutical has ranked among the world's leading manufacturers of macrolide and quinolone APIs. It is also one of China's largest producers of chemical intermediates such as sodium borohydride, potassium borohydride and cyclopropylamine, as well as one of the domestic enterprises with the most comprehensive and extensive product portfolios in the field of animal health APIs. Going forward, with further market exploration of the pet economy, the development potential of Guobang Pharmaceutical will be fully unleashed.
